CurrentBlue KCPolicy POL-PP-312

Testing for Diagnosis of Active or Latent Tuberculosis

Customize your policy alerts

Sign up for Blue KC Policy POL-PP-312 alerts

Get alerted when Policy POL-PP-312 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines coverage and non-coverage for laboratory and diagnostic tests used to diagnose active tuberculosis (TB) and latent TB infection (LTBI) for Blue KC members; applies to professional and facility providers submitting claims.

Policy Summary

PayerBlue KC

PolicyTesting for Diagnosis of Active or Latent Tuberculosis

Policy CodePolicy POL-PP-312

Change TypeAdministrative — no material clinical changes

Effective DateOct 1, 2025

Last ReviewOct 1, 2026

Next Review DateOct 1, 2026

Key ActionVerify member benefits and any required prior authorization before ordering listed TB diagnostic tests.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue KCPolicy POL-PP-312

Testing for Diagnosis of Active or Latent Tuberculosis

Customize your policy alerts

Sign up for Blue KC Policy POL-PP-312 alerts

Get alerted when Policy POL-PP-312 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue KC

PolicyTesting for Diagnosis of Active or Latent Tuberculosis

Policy CodePolicy POL-PP-312

Change TypeAdministrative — no material clinical changes

Effective DateOct 1, 2025

Last ReviewOct 1, 2026

Next Review DateOct 1, 2026

Key ActionVerify member benefits and any required prior authorization before ordering listed TB diagnostic tests.

SourceLink

ReimbursedIGRA for LTBI

ExcludedIGRA for active TB

ReimbursedQualitative NAAT

ExcludedQuantitative NAAT

ExcludedWGS & genotyping

Coverage Criteria for TB Testing

Medically Necessary / Reimbursable Tests

Covered when ANY of the following conditions are met

IGRA for latent TB: Interferon gamma release assay (IGRA) may be reimbursed to diagnose or screen for latent tuberculosis infection in individuals at risk for Mycobacterium tuberculosis infection or when screening is required by law.

Supported for LTBI screening and diagnosis

AFB smear, culture, NAAT: For all suspected TB infections, acid-fast bacilli (AFB) smear/stain, culture with culture-based drug susceptibility testing of Mycobacteria, and qualitative nucleic acid amplification testing (NAAT) for Mycobacteria spp, M. tuberculosis and M. avium complex may be reimbursed.

Includes qualitative NAATs and culture-based methods

LAM testing in advanced HIV: Urine-based detection of mycobacterial lipoarabinomannan (LAM) may be reimbursed for HIV-infected individuals with CD4 ≤ 100 cells/microL who have signs and symptoms of tuberculosis.CD4 ≤ 100 cells/microL

Specific to symptomatic HIV-infected persons

Fluid analysis for suspected extrapulmonary TB: Cell counts, protein, glucose, and lactate dehydrogenase (LDH) concentrations of cerebrospinal, pleural, peritoneal, pericardial, and other fluids may be reimbursed for individuals with pleural effusion, pericardial effusion, or ascites and suspected TB infection.

Supportive fluid testing for extrapulmonary TB evaluation

Molecular Drug Susceptibility Testing — Conditional Coverage

Molecular-based drug susceptibility testing may be reimbursed when ANY of the following are met

Past TB treatment: Individual has been treated for TB in the past.

One qualifying condition

High-risk birthplace or residence: Individual was born in or has lived for at least 1 year in a foreign country with at least a moderate TB incidence (≥ 20 per 100,000) or a high primary MDR-TB prevalence (≥ 2%).see policy

Qualifies for molecular drug susceptibility testing

Contact with MDR-TB case: Individual is a contact of an individual with multidrug-resistant TB (MDR-TB).

Contact exposure qualifies

HIV infection:

Repeat Drug Susceptibility Testing

Repeat drug susceptibility testing may be reimbursed when ANY of the following are met

Persistent positive cultures: Sputum cultures remain positive after 3 months of treatment.3 months

Indication for repeat drug susceptibility testing

Bacteriological reversion: There is bacteriological reversion from negative to positive.

Indication for repeat drug susceptibility testing

Not Medically Necessary / Excluded Tests

Not reimbursed

Tests lacking supportive evidence: Quantitative nucleic acid testing for Mycobacterium spp, M. tuberculosis, and M. avium complex; whole genome sequencing of Mycobacterium spp for detection of drug resistance; genotyping of Mycobacterium spp; testing of adenosine deaminase (ADA) and interferon-gamma (IFN-γ) levels in cerebrospinal, pleural, peritoneal, pericardial, and other fluids for diagnosis of extrapulmonary TB; and testing of serum protein biomarkers or panels for TB detection are not reimbursed due to insufficient published evidence.

Explicit exclusions listed by policy

The policy explicitly excludes several laboratory tests from reimbursement. Quantitative nucleic acid amplification testing (quantitative NAAT) for Mycobacterium spp., including M. tuberculosis and M. avium complex, is not reimbursed. In addition, whole genome sequencing (WGS) of Mycobacterium spp. for detection of drug resistance and genotyping of Mycobacterium spp. are not reimbursed. Testing of adenosine deaminase (ADA) and interferon-gamma (IFN-γ) levels in cerebrospinal, pleural, peritoneal, pericardial, and other body fluids for diagnosis of extrapulmonary TB is not reimbursed. Finally, testing of serum protein biomarkers or panels of biomarkers for TB detection and diagnosis is also not reimbursed.

These exclusions are based on an identified lack of sufficient published scientific evidence demonstrating that the tests are required and beneficial for diagnosis or treatment. Providers should be aware that claims for quantitative NAAT, whole genome sequencing, genotyping, measurement of ADA or IFN-γ in body fluids for extrapulmonary TB, and serum protein biomarker panels may be denied as not reimbursed when submitted.

Coding — Procedure and Diagnosis Codes

Covered/Listed TB diagnostic codesCPTCovered

86480	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon.
86481	Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension.
87206	Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types.
87116	Culture, tubercle or other acid-fast bacilli (eg, TB, AFB, mycobacteria) any source, with isolation and presumptive identification of isolates
87551	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique.
87552	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, quantification.
87556	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique.
87557	Infectious agent detection by nucleic acid (DNA or RNA); mycobacteria tuberculosis, quantification.

Culture identification and susceptibility codesCPTCovered

87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
87153	Culture, typing; identification by nucleic acid sequencing method, each isolate (eg, sequencing of the 16S rRNA gene).
87181	Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip).
87186	Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate.
87190	Susceptibility studies, antimicrobial agent; mycobacteria, proportion method, each agent.

Other NAAT/novel test codesCPT|HCPCS|Other

87561	Infectious agent detection by nucleic acid (DNA or RNA); mycobacteria avium-intracellulare, amplified probe technique.
87562	Infectious agent detection by nucleic acid (DNA or RNA); mycobacteria avium-intracellulare, quantification.
87564	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, rifampin resistance, amplified probe-technique.
0574U	Mycobacterium tuberculosis, culture filtrate protein - 10 - kDa (CFP-10), serum or plasma, liquid chromatography mass spectrometry (LC-MSD) Proprietary Test: NanoDetect - TBTM

Fluid analysis codes (e.g., pleural, pericardial)CPTCovered

83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified.
83615	Lactate dehydrogenase (LD), (LDH).
84157	Protein, total, except by refractometry; other source (eg, synovial fluid, cerebrospinal fluid).
82945	Glucose, body fluid, other than blood.

Foreign residence duration for elevated TB risk — inv-11

ThresholdLived for at least 1 year in a foreign country with TB incidence ≥ 20 per 100,000 or primary MDR-TB prevalence ≥ 2%.

ContextQualifies an individual for molecular-based drug susceptibility testing when sputum is AFB smear positive or NAAT positive.

Applies toIndividuals born in or who have lived ≥1 year in countries meeting the incidence or MDR-TB threshold.

Duration of positive cultures before repeat susceptibility testing — inv-12

ThresholdSputum cultures remain positive after 3 months of treatment.

Provider Actions and Billing Guidance

Prior Authorization

Verify member benefits before ordering

Coverage requires verification of member benefits — Most listed TB diagnostic tests may be reimbursed when clinically indicated and benefit verified. Confirm the individual member's benefit coverage prior to ordering or billing to determine eligibility and any prior authorization or medical necessity documentation requirements.

Affected services: IGRA for latent TB screening, AFB smear/stain, Mycobacterial culture and drug susceptibility testing, Qualitative NAAT for Mycobacteria spp., urine LAM in HIV-infected individuals with CD4 ≤100, fluid analyses (cell counts, protein, glucose, LDH) for suspected extrapulmonary TB.

Documentation Required

Coverage contingent on benefit and intended use

Coverage contingent on benefit and intended use — Application of the policy's coverage criteria depends on the individual's specific benefit plan and the clinical indication. Tests noted as reimbursable are for specified uses (e.g., IGRA for latent TB screening, qualitative NAAT and culture-based testing for suspected TB, molecular-based drug susceptibility testing only when criteria are met).

Background

Infection with Mycobacterium tuberculosis may present as symptomatic active pulmonary disease or as asymptomatic latent tuberculosis infection (LTBI). Culture remains the diagnostic gold standard because it permits organism isolation and drug susceptibility testing. Nucleic acid amplification tests (NAATs) provide sensitive detection of mycobacterial DNA for suspected infections, while interferon-gamma release assays (IGRAs) detect a cellular immune response indicative of latent infection and are reimbursed for LTBI screening when clinically appropriate.

Definitions

IGRA — inv-19

DefinitionInterferon-gamma release assays (IGRAs) are blood tests measuring T-cell release of interferon-gamma after stimulation by M. tuberculosis antigens to detect latent tuberculosis infection (LTBI).

UseMay be reimbursed to diagnose or screen for latent TB infection in individuals at risk or when screening is required by law.

LimitationIGRA is not reimbursed for diagnosing active tuberculosis disease.

NAAT — inv-20

DefinitionNucleic acid amplification tests (NAATs) use polymerase chain reaction (PCR) to enable sensitive detection and identification of low-density Mycobacteria infections.

CoverageQualitative NAATs for Mycobacteria spp, M. tuberculosis, and M. avium complex may be reimbursed for suspected TB infections.

Policy Summary

PayerBlue KC

PolicyTesting for Diagnosis of Active or Latent Tuberculosis

Policy CodePolicy POL-PP-312

Change TypeAdministrative — no material clinical changes

Effective DateOct 1, 2025

Last ReviewOct 1, 2026

Next Review DateOct 1, 2026

Key ActionVerify member benefits and any required prior authorization before ordering listed TB diagnostic tests.

SourceLink

On This Page

Individual is HIV infected.

HIV status qualifies

Indication for repeat drug susceptibility testing (repeat DST) to evaluate ongoing or acquired resistance.

Policy useRepeat DST reimbursed when persistent culture positivity occurs or with bacteriological reversion.

HIV CD4 count threshold for LAM testing — inv-13

ThresholdHIV-infected individuals with CD4 cell counts ≤ 100 cells/microL who have signs and symptoms of tuberculosis are eligible for urine-based LAM testing.

TestUrine-based detection of mycobacterial cell wall glycolipid lipoarabinomannan (LAM).

Clinical noteSpecific to symptomatic HIV-infected persons; used to aid TB diagnosis in advanced immunosuppression.

Molecular-based drug susceptibility testing reimbursable only if: prior TB treatment; born/lived ≥1 year in country with TB incidence ≥20/100,000 or MDR-TB prevalence ≥2%; contact of MDR-TB case; or HIV infection.
Repeat drug susceptibility testing reimbursable for persistently positive cultures after 3 months of treatment or bacteriological reversion from negative to positive.

Denial Risk

Denial triggers for excluded tests

Denial triggers for excluded tests — The following tests do not meet coverage criteria and claims may be denied: quantitative NAAT for Mycobacterium spp./M. tuberculosis/M. avium complex; whole genome sequencing of Mycobacterium spp.; genotyping of Mycobacterium spp.; ADA and IFN-γ testing in body fluids for extrapulmonary TB; testing of serum protein biomarkers or biomarker panels for TB.

Quantitative NAAT (not covered)
Whole genome sequencing (WGS) of Mycobacterium spp. (not covered)
Genotyping of Mycobacterium spp. (not covered)
ADA and IFN-γ testing in CSF, pleural, peritoneal, pericardial, and other fluids for extrapulmonary TB (not covered)
Serum protein biomarkers or biomarker panels for TB detection/diagnosis (not covered)

Note

Provider action: verify coverage and document indication

Provider reminder: When in doubt, contact the payer to verify coverage specifics and required documentation for TB-related testing to avoid claim denials.

Confirm whether IGRA is covered for the intended indication (latent vs active TB).
Document clinical indication and relevant risk factors (e.g., prior TB treatment, travel/residence history, HIV status, contacts with MDR-TB) to support medical necessity.

ExclusionQuantitative nucleic acid testing for Mycobacterium spp, M. tuberculosis, and M. avium complex may not be reimbursed.